Business Context and Reporting Period
Novavax, Inc. (NVAX) filed a Form 8-K on July 30, 2020, reporting the entry into a Material Definitive Agreement. The filing details a strategic partnership with Serum Institute of India Private Limited (SIIPL) regarding the Company's SARS-CoV-2 vaccine candidate, NVX-CoV2373.
Key Financial Metrics
This filing is a current report regarding a material agreement and does not contain financial statements, revenue figures, profit data, cash flow metrics, or debt levels. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreement Terms
The primary material change is the execution of a Supply and License Agreement with SIIPL. Key terms include:
- Licensing Rights: SIIPL received exclusive rights in India and non-exclusive rights in low and middle-income countries (outside the Pandemic Period) and non-exclusive rights in non-high-income countries during the Pandemic Period.
- Revenue Sharing: The parties will equally split revenue from the sale of the Product in SIIPL's licensed territory, net of agreed costs.
- Supply Chain: SIIPL will purchase the antigen drug substance and Matrix-M adjuvant from Novavax.
- Responsibilities: SIIPL is responsible for development, co-formulation, filling, finishing, registration, and commercialization in its territory, subject to joint steering committee oversight.
- Term: The agreement expires 15 years after the first commercial sale in each country. Upon expiration, SIIPL retains a fully-paid, non-exclusive license.
Outlook, Risks, and Contingencies
Management commentary is limited to the description of the agreement's structure. The agreement includes customary representations, warranties, confidentiality, limitation of liability, and indemnity provisions. A key contingency is the definition of the "Pandemic Period" as declared by the World Health Organization, which dictates the scope of non-exclusive rights. The full text of the agreement is to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2020.
Investor Verification Checklist
- Verify the specific definition of "Pandemic Period" and its impact on territory exclusivity.
- Review the full Supply and License Agreement (exhibit to the upcoming 10-Q) for detailed cost-sharing mechanisms and termination clauses.
- Monitor regulatory approval timelines for NVX-CoV2373 in India and other licensed territories.
- Assess SIIPL's manufacturing capacity and track record for vaccine commercialization.